Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Bioxcel Therapeutics Inc (BTAI)

$3.17 +0.06 (1.93%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	49.79M
Revenue (ttm)	2.27M
Net Income (ttm)	-59.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,625.55%
Debt to Equity Ratio	-1.01

Volume	2,188,200
Avg Vol	11,971,878
Day's Range	N/A - N/A
Shares Out	16.01M
Stochastic %K	2%
Beta	0.20
Analysts	Sell
Price Target	$7.75

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Biotechnology

Sector: Healthcare

Phone: 475 238 6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

Advance33 Sep. 16 at 5:45 AM

$EDGM $BTAI $WLGS

0 · Reply

FRENESY Sep. 16 at 2:19 AM

$BTAI BAMM HOW YA DOIN !!

1 · Reply

Sw1ngb0t Sep. 16 at 1:09 AM

$BTAI also flagging nicely on the 15 min

1 · Reply

Sw1ngb0t Sep. 16 at 1:07 AM

$BTAI $9.50 target for me on the weekly chart so $10 for sure

0 · Reply

Roboticai Sep. 16 at 1:04 AM

$BTAI

0 · Reply

AnnWinstead691 Sep. 16 at 12:37 AM

$TSLA $MSN $AEI $XFOR $BTAI 2.

0 · Reply

Sw1ngb0t Sep. 16 at 12:21 AM

$BTAI two red candles below $4.04 on the weekly is all they get

0 · Reply

Trade_catcher Sep. 16 at 12:10 AM

$BTAI interesting move up before close

0 · Reply

YoMommaLikesMyGlaze Sep. 15 at 11:20 PM

$BTAI shorts wall @ 320

0 · Reply

BunterHiden Sep. 15 at 11:18 PM

$BTAI new 52 week low this week or next

1 · Reply

BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)

Sep 10, 2025, 3:08 PM EDT - 5 days ago

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

Sep 10, 2025, 6:30 AM EDT - 5 days ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 4, 2025, 7:00 AM EDT - 11 days ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 12:01 PM EDT - 19 days ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 8:00 AM EDT - 19 days ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 7:29 AM EDT - 19 days ago

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:00 AM EDT - 19 days ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 26, 2025, 4:00 PM EDT - 20 days ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 19, 2025, 7:00 AM EDT - 27 days ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 4 weeks ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 13, 2025, 7:00 AM EDT - 4 weeks ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 1, 2025, 7:00 AM EDT - 6 weeks ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 21, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 1, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 3 months ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 27, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 6 months ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 6 months ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 7 months ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 7 months ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 28, 2025, 7:00 AM EST - 7 months ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 5, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 9, 2024, 9:48 PM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

Jul 16, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

May 28, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

May 21, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

May 9, 2024, 9:53 AM EDT - 1 year ago

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Apr 22, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia

Mar 25, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

Mar 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Mar 12, 2024, 11:00 AM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript

Advance33 Sep. 16 at 5:45 AM

$EDGM $BTAI $WLGS

0 · Reply

FRENESY Sep. 16 at 2:19 AM

$BTAI BAMM HOW YA DOIN !!

1 · Reply

Sw1ngb0t Sep. 16 at 1:09 AM

$BTAI also flagging nicely on the 15 min

1 · Reply

Sw1ngb0t Sep. 16 at 1:07 AM

$BTAI $9.50 target for me on the weekly chart so $10 for sure

0 · Reply

Roboticai Sep. 16 at 1:04 AM

$BTAI

0 · Reply

AnnWinstead691 Sep. 16 at 12:37 AM

$TSLA $MSN $AEI $XFOR $BTAI 2.

0 · Reply

Sw1ngb0t Sep. 16 at 12:21 AM

$BTAI two red candles below $4.04 on the weekly is all they get

0 · Reply

Trade_catcher Sep. 16 at 12:10 AM

$BTAI interesting move up before close

0 · Reply

YoMommaLikesMyGlaze Sep. 15 at 11:20 PM

$BTAI shorts wall @ 320

0 · Reply

BunterHiden Sep. 15 at 11:18 PM

$BTAI new 52 week low this week or next

1 · Reply

YoMommaLikesMyGlaze Sep. 15 at 11:17 PM

$BTAI shorts better cover soon, any day

0 · Reply

OTC85 Sep. 15 at 11:10 PM

$EDGM $BTAI $WLGS

0 · Reply

YoMommaLikesMyGlaze Sep. 15 at 11:03 PM

$BTAI 5 decimal points shorts really nervous

0 · Reply

YoMommaLikesMyGlaze Sep. 15 at 11:00 PM

$BTAI ah short algo running after hours

0 · Reply

NobVega Sep. 15 at 10:45 PM

$BTAI The company will announce compliance after the close tomorrow or premarket Sep 17. Standing by. Longs have been waiting too long for revenge day. Let's do it.

1 · Reply